Vaccines

Therapeutic Areas

 

shutterstock_360472571 

Several diseases are characterized by an overproduction of cytokines. This overproduction is responsible for autoimmune, inflammatory diseases, allergies and certain types of cancers.  The specificity of Neovacs Kinoid® technology makes cytokines immunogenic when they are not naturally – a revolutionary therapeutic innovation that provides an important treatment opportunity in the fields of autoimmune and inflammatory diseases. Today, the company is focusing its development efforts on offering patients new therapeutic options based on its Kinoid® vaccines.

 

IFNα KINOID AND LUPUS

SYSTEMIC LUPUS ERYTHEMATOSUS(SLE) OR LUPUS ERYTHEMATOSUS DISSEMINATED (LED)

Systemic lupus erythematosus (SLE) or lupus erythematosus is a debilitating, chronic autoimmune disease whose etiology remains unknown. SLE is characterized by a loss of tolerance of self-antigens, with the production of autoantibodies, especially antinuclear antibodies that attack healthy tissues and cause inflammatory reactions in different parts of the body. The disease can affect multiple organs (skin, kidneys, joints, heart, lungs, central nervous system, etc. ) and is characterized by heterogeneous clinical signs (skin rashes, arthritis, photosensitivity, nephritis, neurological disorders, anemia, thrombocytopenia, etc.), which vary from one person to another and change during the progression of the disease. Systemic lupus erythematosus affects mostly women.

 

EPIDEMIOLOGY OF SYSTEMIC LUPUS ERYTHEMATOSUS

 

  • the overall annual incidence reached 3.32 cases per 100,000 people
  • the disease affects mostly women. (9 women/1 man)
  • the disease is mainly diagnosed in patients aged between 15 to 45 years.

In its successfully completed Phase I/IIa clinical study in lupus, Neovacs has already demonstrated that anti-interferon antibodies have a biological activity capable of neutralizing the IFNα signature in Systemic Lupus Erythematous (SLE) patients immunized with IFNα kinoid.  In addition, the treatment is well tolerated with a long lasting immune response. (Lauwerys Arthritis&Rheum 2013 and Ducreux 2016 Rheumatology)

Neovacs is actually running an international  Phase IIb clinical study in Lupus, under “IND” and has been granted a “Fast Tracks ” designation by the U.S FDA. (Find more information about this study on clinicaltrials.gov

 

 

IFNα KINOID AND DERMATOMYOSITIS

DERMATOMYOSITIS

Dermatomyositis is a rare autoimmune idiopathic inflammatory myopathy characterized by muscle weakness and characteristic skin  lesions (heliotrop rash and Gotron papules).The disease can also affect the vascular, cardiac  and gastrointestinal systems. Pulmonary manifestations can also be observed, sometines with severe complications.

The disease affects mostly children (60% of patients). In adults, one in three patients with Dermatomyositis develops cancer within three years of the diagnosis.  Dermatomyositis has a prevalence between 1 case per 50 000 and 1 case per 10 000 and  is twice as common in women as in men. It has the status of an orphan disease in Europe and United States.

Neovacs is conducting a Phase IIa clinical study for this disease. (Find more information about this study on clinicaltrials.gov)

IFNα KINOID AND TYPE 1 DIABETES

Diabetes is a disease that affects, according to WHO**, 422 million people worldwide, including 4 million in France and a rapid progression that could include 622 million patients by 2040. Notably, 10% of these patients have the auto immune form of type 1 diabetes.

Neovacs is working on a proof of concept in collaboration with Doctor Agnès Lehuen and Professor Christian Boitard, who are leading the laboratory for Research in Immunology of Diabetes at Cochin Hospital in Paris, France.

The goal of this collaboration is to achieve proof of concept for the use of Neovacs’ IFNa Kinoid in the treatment of Type 1 diabetes.

Image Alt Text

VEGF KINOID, OVARIANS AND COLORECTAL CANCERS

Neovacs’ technology provides a significant new therapeutic opportunity for the types of cancers where the VEGF-A (vascular endothelial growth factor) protein plays an important role in the vascularization of the tumor. Neovacs’ approach, based on active immunotherapy, aims to enhance the patient’s immune system by enabling it to produce self-polyclonal antibodies, which will selectively target and neutralize the cytokine VEGF-A. For these types of cancers, the neutralization of VEGF-A could prevent tumor growth and the development of metastases.

Neovacs is collaborating with the SUNNYBROOK RESEARCH INSTITUTE on the preclinical development of VEGF Kinoid to treat colorectal cancer and ovarian cancer.

Why should you invest in Neovacs ?

Go to the investors section